A Study to Observe Pure Red Cell Aplasia (PRCA) Occurrence in Patients with Chronic Kidney Disease Who Used Hema-Plus (Recombinant Human Erythropoietin Alfa) at Ramathibodi Hospital

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20170807003

Enrollment

Registered

2017-08-07

Start date

2017-07-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

Patients who presented with chronic kidney disease (CKD) and had history of receiving Hema&#45

Plus for at least 12 months during the study period.

Other

Treatment group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Each patient included in the review must meet all of the following criteria to be in this study: 1. Presented with chronic kidney disease (CKD). 2. History of receiving Hema-Plus for at least 12 months during the study period.

Exclusion criteria

Exclusion criteria: Patients who met inclusion criteria but their medical records are not available for access.

Design outcomes

Primary

Measure	Time frame
Event Pure Red Cell Aplasia (PRCA) After treated by study drug Number of PRCA case from medical record review,Hema-Plus treatment dose and exposure time After treated by study drug dose and duration of Hema-Plus treatment which receive from medical record review	—

Secondary

Measure	Time frame
NA NA NA	—

Countries

Thailand

Contacts

Public ContactNarumon Werayingyong

Siam Bioscience Co., Ltd.

narumonw@siambioscience.com02 613 9939

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

A Study to Observe Pure Red Cell Aplasia (PRCA) Occurrence in Patients with Chronic Kidney Disease Who Used Hema&#45;Plus (Recombinant Human Erythropoietin Alfa) at Ramathibodi Hospital